ROVI has obtained the best ESG score from among the 458 companies evaluated in its pharmaceutical subindustry category.
EIB and ROVI are signing a EUR 50 million loan agreement in Madrid for research, development and innovation.
Moderna and ROVI Pharma Industrial Services, S.A.U. today announced a recall of one lot (lot #000190A) of the Moderna COVID-19 vaccine (Spikevax®)
The achievement of this important milestone responds to the Environmental and Social Sustainability Policy of the Group and to the efforts that performs to reduce the environmental impact of all its activities.
Moderna and ROVI expand long-term collaboration for the manufacture of mRNA medicines over the next ten years
Long-term agreement includes a series of investments to acquire new equipment and adapt the present ROVI drug product fill-finish facilities and production lines in Spain
Risperidone ISM® is a prolonged-release injectable antipsychotic developed and patented by ROVI for the treatment of schizophrenia in adults for whom tolerability and effectiveness has been established with oral risperidone